drugset / Trial / NCT07532603
A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
RandomizedParallel-groupTriple-blindTreatment
Summary
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris
Timeline
- Start
- 2026-03-19
- Primary completion
- 2028-12-31
- Completion
- 2029-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brepocitinib | Small molecule | — | Oral |